FDA Brief

Warning letters Drugs

FDA warning letter to

Fuller Industries Inc.

High riskIssued Jun 28, 2023Posted Jul 18, 2023Division of Pharmaceutical Quality Operations III

FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

What happened

FDA inspected Fuller Industries' drug manufacturing facility in Great Bend, Kansas, from February 15 to 17, 2023. The agency found that the company's quality unit did not adequately oversee manufacturing, including missing active-ingredient testing and investigations, and that the company failed to properly test propylene glycol and ethanol for hazardous impurities. FDA also found the company used a non-validated internet method for total solids testing and called the company's March 2, 2023 response inadequate.

What FDA found

  1. The quality unit did not ensure chloroxylenol assay testing was performed, documented, and reviewed for every batch of antibacterial foam hand soap before release.

    21 CFR 211.165(a), 211.160(a), 211.22(c)
  2. Some chloroxylenol assay results appeared out of specification, and pH issues were not thoroughly investigated.

    21 CFR 211.192
  3. The company failed to establish an adequate ongoing stability program and annual product reviews.

    21 CFR 211.166(a), 211.180(e)
  4. The company did not adequately test each propylene glycol lot for identity, including the USP limit test for diethylene glycol and ethylene glycol, and relied on supplier certificates without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The company did not appropriately test incoming ethanol for impurities such as methanol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  6. The company used a non-validated total solids test method from an internet search that was not specific or appropriate for its drug products.

    21 CFR 211.160(b)

What FDA wants

FDA tells Fuller to correct the violations promptly and respond in writing within 15 working days with corrective actions, assessments, and remediation plans. FDA also recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands and retailers that buy OTC hand soaps or sanitizers from this manufacturer
  • contract manufacturers relying on supplier certificates of analysis for propylene glycol or ethanol
  • quality and regulatory teams responsible for OTC topical drug CGMP

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk